NICE recommends cannabis-based Epidyolex to treat seizures

Pharmaceutical Technology | November 11, 2019

The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of GW Pharmaceuticals’ cannabis-based medicine Epidyolex (cannabidiol) for routine treatment on the National Health Service (NHS) to treat seizures. Epidyolex is plant-derived medicine in the form of an oral solution, used as an adjunctive treatment for seizures caused by Lennox Gastaut syndrome (LGS) and Dravet syndrome in patients aged two years and above. The oral solution secured approval and marketing authorisation from the European Medicines Agency in September. However, in its draft guidance, NICE said that the drug was not cost-effective, reported BBC. The medicine costs around £5,000 to £10,000 per patient each year. The latest NICE recommendation comes as GW Pharmaceuticals has agreed on a discount price with the NHS. Studies show that the cannabidiol oral solution, in combination with other anti-epileptic therapies, significantly decreases the seizure frequency in patients with LGS and Dravet syndrome.

Spotlight

The Pharma industry is increasing its focus on developing Specialty drugs. It is expected to grow by 67% in 2015 alone, while the overall Specialty drug spending is expected to more than quadruple by 2020, accounting for about $402 billion a year in sales. While opinions vary on the exact definition of Specialty Pharma, it can be defined as an industry with an unconventional Pharmaceutical business model that focuses on specialized therapeutic segments, including oncology.

Spotlight

The Pharma industry is increasing its focus on developing Specialty drugs. It is expected to grow by 67% in 2015 alone, while the overall Specialty drug spending is expected to more than quadruple by 2020, accounting for about $402 billion a year in sales. While opinions vary on the exact definition of Specialty Pharma, it can be defined as an industry with an unconventional Pharmaceutical business model that focuses on specialized therapeutic segments, including oncology.

Related News

PRACTICE MANAGEMENT

AvKARE bottles mix Viagra generics with antidepressant, triggering recall

AvKARE | December 15, 2020

A conventional drugmaker with a Rolodex loaded with government customers is pulling an energizer and an erectile brokenness medications after the two were bundled together in similar containers. Pulaski, Tennessee-based AvKARE reviewed one parcel of sildenafil 100-mg tablets and one parcel of trazodone 100-mg tablets after the items were stirred up by an outsider bundling provider, the organization said before the end of last week. The jugs had just been delivered to drug stores. AvKARE markets its own private-name conventional medications to a record of government customers, including the branches of Defense, Veterans Affairs and the Health and Human Services. The organization additionally supplies the Indian Health Services, in addition to nongovernment clients around the world. The customer level review influences parts sent to merchants and wholesalers and afterward delivered out from one side of the country to the other, the organization said. The sildenafil part has a March 2022 termination date, while the trazodone parcel lapses in June 2022. AvKARE said it so far hasn't got any result reports from the reviewed parcels. Sildenafil—a nonexclusive rendition of Viagra—can blend inadequately with nitrate-containing drugs for diabetes, hypertension or coronary illness, conceivably bringing pulse down to perilous levels. The upper trazodone hydrochloride, in the interim, can cause sluggishness, dazedness, stoppage and obscured vision, AvKARE cautioned. Those results represent a more serious danger of falls and impeded driving in more seasoned clients who may have bought the organization's erectile brokenness copycat.

Read More

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

OBI Pharma | September 14, 2020

OBI Pharma, Inc, a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020. The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be led by Ming-Tain Lai, PhD. Chief Scientific Officer at OBI Pharma. The presentation will highlight the results from pre-clinical studies of OBI Pharma's first-in-class anti-Globo H antibody drug conjugate (OBI-999), including animal efficacy and safety data, supporting the ongoing Phase 1/2 human study ongoing at the MD Anderson Cancer Center in Houston, TX (USA).

Read More

PHARMA TECH

CareRx Applauds Ontario Ministry of Health's Pause of Planned Fee Changes

CareRx | January 18, 2021

CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of specialty pharmacy services to seniors, is pleased that the Ontario Ministry of Health has announced that it will pause for one year previously scheduled changes to long-term care pharmacy funding, which were scheduled to go into effect on April 1, 2021. Under certain amendments to the Ontario Drug Benefit Act that came into effect on January 1, 2020, the reimbursement model for long-term care pharmacies in Ontario was changed from a fee-for-service model to a fee-per-bed capitation model under which pharmacies receive a fixed professional fee for all pharmacy services provided to residents in long-term care homes. The fee for 2020, which was prescribed at $1,500, was scheduled to decline to $1,400 per bed serviced on April 1, 2021. The step-down in capitation has now been paused until April 1, 2022. "Long-term care homes and their staff have faced unprecedented challenges during COVID-19," said David Murphy, President and Chief Executive Officer of CareRx. "This pause will ensure that pharmacies like CareRx can continue to deliver the same exceptional partnership and service offering to long-term care homes and help alleviate the burden COVID-19 has placed on home staff. We want to thank Minister Elliott, Minister Fullerton and the Ontario Government for their ongoing dialogue and commitment to protecting the wellbeing of residents in long-term care." About CareRx Corporation CareRx is Canada's leading provider of specialty pharmacy services to seniors. We serve approximately 50,000 residents in over 900 seniors and other communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

Read More